youtube_live
Q3 2026 earnings • 2:30 PM tomorrow
See detailschevron_right
BIIB34:BVMF
Biogen Inc BDR
R$193.80
0.00%
(0.00) 1D
Oct 14, 12:51:04 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
37.27B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.75M
No. of employees
8K
Mkt. cap
37.27B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
Biogen earnings: what to look for from BIIB
TradingView
·
1 day ago
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com